A novel role for APOBEC3: Susceptibility to sexual transmission of murine acquired immunodeficiency virus (mAIDS) is aggravated in APOBEC3 deficient mice
© Jones et al.; licensee BioMed Central Ltd. 2012
Received: 14 March 2012
Accepted: 16 May 2012
Published: 12 June 2012
APOBEC3 proteins are host factors that restrict infection by retroviruses like HIV, MMTV, and MLV and are variably expressed in hematopoietic and non-hematopoietic cells, such as macrophages, lymphocytes, dendritic, and epithelia cells. Previously, we showed that APOBEC3 expressed in mammary epithelia cells function to limit milk-borne transmission of the beta-retrovirus, mouse mammary tumor virus. In this present study, we used APOBEC3 knockout mice and their wild type counterpart to query the role of APOBEC3 in sexual transmission of LP-BM5 MLV – the etiological agent of murine AIDs (mAIDs).
We show that mouse APOBEC3 is expressed in murine genital tract tissues and gametes and that genital tract tissue of APOBEC3-deficient mice are more susceptible to infection by LP-BM5 virus. APOBEC3 expressed in genital tract tissues most likely plays a role in decreasing virus transmission via the sexual route, since mice deficient in APOBEC3 gene have higher genitalia and seminal plasma virus load and sexually transmit the virus more efficiently to their partners compared to APOBEC3+ mice. Moreover, we show that female mice sexually infected with LP-BM5 virus transmit the virus to their off-spring in APOBEC3-dependent manner.
Our data indicate that genital tissue intrinsic APOBEC3 restricts genital tract infection and limits sexual transmission of LP-BM5 virus.
KeywordsAPOBEC3 murine AIDS LP-BM5 virus MLV ♀: female ♂: male
Viruses that use the genital mucosa as a portal of entry into the host include HPV, HSV, hepatitis B virus, and retroviruses like SIV, MLV, and HIV. Worldwide, HIV infection is pandemic in many countries and is primarily transmitted from infected persons to their sexual partners through contact with infected semen and vaginal secretions [1–4]. The control of sexual transmission is, therefore, pivotal to curbing the HIV pandemic, especially since the genital tract may also serve as a sanctuary in which HIV undergoes selective pressures [5–8] that may result to the emergence of drug-resistant HIV variants that may be sexually transmitted [9–11]. Indeed, it is known that patients with highly active anti-retroviral therapy (HAART) - suppressed plasma viral load continue to shed viral RNA through the genital tract [12, 13]. It is therefore critical to determine whether host factors can control virus replication and evolution within the male genital tract. Since we could not use human subjects for these experiments, a mouse model offers a practical alternative. Hence, we utilize the murine acquired immunodeficiency syndrome (mAIDs) model.
mAIDs is a mouse retroviral disease caused by the viral complex LP-BM5 . LP-BM5 is a mixture of murine leukemia viruses comprised of the replication competent helper virus BM5e, the mink cell cytopathic focus-inducing virus, and the replication-defective virus BM5def, responsible for the immunodeficiency [15, 16]. Infection of susceptible mice with LP-BM5 causes severe immunodeficiency syndrome similar to human AIDS [14, 17]. Some of the similar characteristics between mAIDS and hAIDS include hypergammaglobulinemia, lymphadenopathy, severely depressed T- and B-cell responses to mitogens, increased susceptibility to infection, disease progression and the development of B-cell lymphomas and splenomegaly [18–22]. Despite the similarities between mAIDS and hAIDS, differences between the two infectious diseases exist. Unlike human AIDS, mice suffering from mAIDS develop mediastinal lymph node enlargement and may die of respiratory failure . Propagation of mAIDS in mice requires the matrix (MA) and p12 of the Gag gene of BM5def . Due to the similarity in virus transmission and disease outcome between LP-BM5- and HIV infections, mAIDs is a good model for examining sexual transmission of HIV and have been used for the initial evaluation of new drugs [25–29].
To be transmitted sexually, HIV and LP-BM5 will have to overcome host resistance in genital mucosal surfaces which are composed of different types and layers of epithelial cells and mucosa-associated lymphoid tissues (MALTs). The male and female genital mucosal layers are filled with cells of the immune system, including dendritic cells (DCs), macrophages and lymphocytes [30–36]. The immune cells in the genital mucosal surfaces express pattern recognition receptors (PRRs) such as Toll-like receptors, RIG-I-like receptors, and NOD-like receptors [37–40] that function to recognize different pathogen associated molecular patterns (PAMPs) and stress signals leading to activation of the host innate and adaptive immune responses. Aside from innate and adaptive immune responses elicited by cells in the genital mucosal surfaces, the expression of anti-viral genes such as APOBEC3 (A3) in male reproductive organs has been reported [41, 42].
A3 proteins are virus restriction factors that encode DNA-editing enzymes. The human genome encodes 7 A3 genes (A3 –A, -B, -C, -D/E, -F, -G, -H), and the mouse genome encodes only 1 A3 gene . A3 proteins are variably expressed in hematopoietic and non-hematopoietic cells, and in different tissues [42, 44–47]. The most studied human A3 genes (A3G and A3F) and mouse A3 (mA3) are reported to confer intrinsic immunity to HIV-1 and other viruses including MMTV and MLV [45–52]. In the absence of HIV-1 viral infectivity factor (Vif), A3F and A3G are packaged into progeny virions via interactions with the nucleocapsid (NC) protein and viral RNA. A3 proteins then inhibit infection in target cells by deaminating deoxycytidine residues on the DNA minus strand following reverse transcription and inducing mutations in newly synthesized HIV-1 DNA. In addition, A3F and A3G degrade reverse transcribed viral DNA prior to integration and induce mutation of viral genes in the integrated provirus [53–56]. However, in the presence of Vif, A3F and 3G are marked for proteasomal degradation [57–59], thus preventing their packaging into progeny virions; resulting in productive infection of target cells. Furthermore, there is growing evidence that A3 proteins can restrict HIV and other viral infection in a deamination independent manner [45, 46, 60, 61]. We previously showed that endogenous mA3 restricts MMTV infection in vivo in a deamination independent mechanism . In addition to limiting virus replication, we recently demonstrated that the rate of milk-borne transmission of MMTV was significantly increased in mice harboring targeted mutation in the mA3 gene , demonstrating that A3 proteins play a role in containing milk-borne virus transmission.
In the present study, we define the role of A3 in sexual transmission of retroviruses using the mAIDs model and mice with targeted mutation in the mA3 gene. Our data indicate that mice with targeted mutation of APOBEC3 gene have a higher rate of sexual transmission compared to the wild type control, suggesting a role for APOBEC3 in limiting sexual transmission.
mA3 is expressed in genital tract tissues and gametes
mA3-deficient mice have increased susceptibility to acute LP-BM5 infection
mA3 deficiency exacerbates mAIDs-associated lympho-proliferation and splenomegaly
Mice lacking mA3 gene have higher genital infection and seminal plasma virus load
Loss of APOBEC3 gene facilitates efficient sexual transmission of LP-BM5
Female mice sexually infected with LP-BM5 transmit the virus to their off-spring in APOBEC3-dependent manner
mA3 genotype permutation for the generation of off-springs from parents of different genetic backgrounds
Off-spring mA3 genotype
♂ 159 -/-
♀ 159C +/-
♂ 160 +/-
♀ 160C -/-
♀ 160D WT
♂ 161 WT
♀ 161D +/-
Genital organ mA3 determines susceptibility to sexual transmission
HIV is mostly propagated worldwide through sexual transmission. While a number of host factors have been identified to enhance sexual transmission of HIV , factors that limit sexual transmission of HIV have not been described. However, APOBEC3 as an anti-HIV factor that restricts infection of hematopoietic and non-hematopoietic cells [47, 50] could potentially play a role in sexual transmission. Recently, in vivo studies in mice show that APOBEC3 restricts MMTV infection of the lymphoid compartment, resulting in lower levels of virus infection in mammary tissue, accompanied by a decreased rate of milk-borne transmission of MMTV .
Here, we demonstrate a possible role for APOBEC3 in restricting a sexually transmitted virus infection. We show that mice with targeted deletion of the Apobec3 gene have higher rates of LP-BM5 infection in lymphoid and genital tissues, and that this results in enhanced rates of sexual transmission of LP-BM5 virus. It is known that LP-BM5 infects genital tissues  and causes severe immunodeficiency and splenomegaly [18–22]. APOBEC3 is made in genital organs; interestingly, the absence of APOBEC3 in these organs, as in APOBEC3 knockout mice, altered infection of the genital organs. Higher level of infection in APOBEC3 knockout mice provides evidence that APOBEC3 mediates the susceptibility of the genitalia and gametes to virus infection. Additionally, the significantly higher vRNA in genital organs of APOBEC knockout mice (Figure 4I), as well as high levels of extracellular vRNA and protein in seminal plasma (Figure 4E and 4G) from APOBEC3 knock mice indicates that LP-BM5 is actively replicating more efficiently in the absence of APOBEC3. Our finding is in line with published reports [75, 76] which showed the occurrence of active virus replication in semen of HIV-1 infected men. The alteration of virus infection in genital compartment in APOBEC3 knockout mice positively correlates with high level of viral RNA in seminal plasma, as well as increased infectivity of seminal plasma LP-BM5 virus compared to wild type mice. The demonstration that extracellular virions from seminal plasma obtained from APOBEC3 knockout mice are more infectious than that from control mice further confirms that loss of mA3 results in higher virus load (Figure 4H). These results suggest that genital organ-intrinsic APOBEC3 expression serves to limit sexual transmission of LP-BM5, and perhaps other retroviruses. Indeed, we show that seminal fluid of APOBEC3 knock mice harbors more LP-BM5 virus compared to the wild type as visualized by Western blot (Figure 4G), but we were unable to detect APOBEC3 due to perhaps the lack of good anti-mouse APOBEC3 antibodies or limited viral protein in samples from APOBEC3 sufficient mice. The detection of LP-BM5 proviral DNA in spermatozoa and testes support previous observations made with HIV-1 and herpesvirus type 8 [77–80].
Using genetic studies, we found that APOBEC3 mediates rate of sexual transmission of LP-BM5. The different permutations of genetic backgrounds used clearly show that the APOBEC3 gene is critical in determining the outcome of sexual transmission of LP-BM5 from one partner to the other, and from a sexually infected mother to her off-spring through nursing. Although loss of APOBEC3 enhanced rate of sexual transmission, we also observed that APOBEC3 deficient female mice were more highly infected compared to the heterozygote and wild type controls in that order. These genetic experiments show that APOBEC3 also plays a crucial role in mediating virus acquisition from an infected male and that the female genetic background contributes in defining the outcome of infection.
We also used adoptive transfer and in vivo genetic experiments to demonstrate a clear relationship between genital-intrinsic APOBEC3 and sexual transmission. Genital-intrinsic APOBEC3 mediates control of sexual transmission since higher levels of splenocyte infection observed in male mice that received APOBEC3 knockout cells did not translate to higher rate of female partner infection. This concept was further confirmed by similar level of infection observed in the off-springs of these mice irrespective of the male parent splenocyte APOBEC3 genotype.
While murine retroviruses (beta and gamma retroviruses) are sensitive to A3 antiviral activity, they have also successfully replicated in mice. It is not clear how these infectious viruses have evaded host restriction to achieve efficient replication, since they do not encode viral accessory proteins, such as the HIV-1 Vif protein that antagonizes some human A3 proteins. However, reports of alternative mechanisms used by murine retroviruses to evade restriction by A3 proteins exist. Indeed, MLV virions have been shown to exclude mA3  as well as inactivate mA3 by viral protease , and xenotropic murine leukemia-virus related virus (XMRV) down-regulates hA3G in prostate cancer cells .
Sexual transmission of HIV-1 continues to be a problem worldwide, especially in developing countries, where access to condoms is restricted by cultural and socio-economic situations. Previous studies have indicated that the use of HAART in the control of HIV transmission has mixed results since some HAART treated patients with suppressed plasma viral load continue to shed viral RNA in semen [12, 13].
As in immune cells and mammary epithelia cells, APOBEC3 is made in genital organs and gametes. Based on our data, we suggest that APOBEC3 expression in genital organs and gametes may have been retained as a means of inhibiting sexual transmission of viruses. In addition, APOBEC3 in genital organs could have important therapeutic implications for sexual transmission of viruses. For example, therapeutics could be developed that increase APOBEC3 level in genital organs, resulting in attenuated virions.
Experiments involving the use of mice were performed in accordance to NIH guidelines, the Animal Welfare Act, and US federal law. Experiments were approved by the University of Iowa Animal Care and Use Committee (IACUC).
MEF and primary testicular cells were obtained from mA3-/-, mA3+/-, and WT mice on C57BL/6 background. SC1-G6 cells chronically infected with LP-BM5 (containing ecotropic, mink cell focus-forming and defective viruses) were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH from Dr. Herbert Morse and Dr. Janet Hartley [15, 19, 23].
The mA3-knockout (mA3-/-) and matched controls mA3+/-, (mA3+/+, WT) mice have been previously described . All mice were housed according to the policies of the Institutional Animal Care and Use Committee of the University of Iowa.
Five age-matched (5 weeks old) male mice of each genotype were lethally irradiated with gamma rays. All radiation experiments were performed at the Radiation and Free Radical Research Core Facility of the University of Iowa. Mice were irradiated with a dose of 9 Gy (dose rate, 0.345 Gy/min) using a 137Cs source (JL Shepherd, San Fernando, CA) as previously described . Four hours after irradiation, mice were reconstituted with bone marrow stem cells from either mA3-/- or WT mice. Four weeks after reconstitution, the mice were inoculated with LP-BM5 virus. Prior to infection, peripheral blood lymphocytes from each mouse were subjected to FACs analysis with conjugated anti-mouse CD8, CD4, CD11c and B220, to test for uniform reconstitution.
Cell-free LP-BM5 viral mixture was prepared from chronically infected SC-l cells as previously described . Culture supernatants were collected and centrifuged at 1500 rpm for 10 minutes to clarify cellular debris. Clarified culture supernatants were filtered through a 0.45 μM filter, layered on to 20% sucrose cushion and centrifuged at 7000 rpm, 4 °C overnight. Virus pellet was resuspended in PBS at 10:1 ratio and aliquots of 100 μl stored at -80 °C until required for use.
Cell and mouse infection
Infection of cells with cell culture or seminal plasma virus was done in triplicates in 96-well plate format. Briefly, primary testicular cells or splenocytes were plated at ~100,000 cells per well. Twenty four hours later, cells were incubated with 8 μg/ml of polybrene for 2 hours. Polybrene-containing medium was removed and replaced with 100 μl of virus-containing medium or PBS for control. Cells were spinoculated at 1200 rpm for 2 hours at room temperature. Following spinoculation, cells were incubated at 37 °C for 24 hours. DNA was extracted from cells for examination of viral load. Mice infections were done either subcutaneously (SubQ) on the hind footpad or intraperitoneally (IP). For footpad inoculation, 30 μl of virus or PBS was injected into the footpad tissue and IP inoculation was performed with 200 μl of virus or PBS. At the appropriate time depending on experiment, mice were sacrificed and relevant tissues obtained for downstream analysis.
Genotyping mA3 -/- mice
Mice genotypes were determined using two parallel PCRs as previously described . Briefly, DNA was extracted and 50 ng of genomic DNA and 25 pmol of primers were used in a total volume of 25 μl PCR reaction. PCR amplicons were separated on a 2% agarose gel.
Nucleic acid isolation and real-time quantitative PCR
Milk and seminal plasma viral loads were determined for BM5def as previously described . Briefly, total RNA was isolated from seminal fluid (200 μl) or milk (50 μl) samples using Trizol RNA Reagent (AMRESCO). Isolated RNA was DNAsed and subjected to cDNA synthesis (Applied Biosystems, ABI) as previously described . DNA was also isolated from different tissues using QIAGEN-QIAamp DNA Mini Kit following manufacturer’s recommendation. Nucleic acid concentration and purity were measured spectrophotometrically at 260/280 nm. DNA and cDNA were amplified with primers and probe specific to BM5def  and GAPDH using ABI 7500 FAST thermal cycler (ABI).
Approximately, 1 × 106 splenocytes were stained in PBS + 1% bovine serum albumin (Sigma-Aldrich) for 30 minutes on ice with APC-, FITC-, and PE-conjugated antibodies and the resulting immunofluorescence was analyzed by use of a FACSCalibur flow cytometer (BD) to detect the expression of murine CD69, B220, and CD4 (BD or eBioscience). Cellular frequency and fluorescence intensity were determined by Flowjo analysis software (TreeStar). APC-, FITC-, and PE-conjugated Ig isotypes of irrelevant specificity were used as control for each monoclonal antibody.
Western blots of virus preparations and cell extracts were probed with anti-p30 (MLV capsid) and anti-GAPDH. The species-appropriate IRDye secondary antibodies were used, followed by detection with the Odyssey Infrared Imaging System (LI-COR Biosciences).
Virus purification from seminal plasma
The seminal samples obtained from epididymis were processed immediately and pooled within genotype to provide sufficient seminal plasma volume and seminal cells. Pooled epididymal seminal samples were centrifuged for 15 minutes at 400 g. The pellet was further purified to obtain pure sperm cells as discussed below. The supernatant was collected and filtered through a 0.45 μM filter. Virions were purified from the supernatants by ultracentrifugation at 40,000 rpm for 30 minutes. Viral pellet was resuspended in PBS and stored in 50 μl aliquots at -80 °C until required for use.
Pooled epididymal seminal samples were subjected to standard swim-up technique to purify sperm cells. Briefly, semen samples were centrifuged for 15 min at 400 g. The pellets were resuspended in pre-warmed 2.5 ml Ham's F-10 culture medium (Sigma) supplemented with 10% human serum albumin. Cells were layered over equivalent volume of 80% Percoll and 40% Percoll and centrifuged for 15 minutes at 400 g as previously described . The supernatant was discarded and the pellet was resuspended in Ham's F-10 culture medium and thereafter centrifuged for 15 minutes at 400 g. The supernatant was removed and the pellet was overlaid with 2.5 ml Ham's F-10 medium and incubated for 60 min in 5% CO2 at 37 °C to allow spermatozoa to swim up from the pellet. A sterile Pasteur pipette was used to remove the supernatant containing actively motile sperms. A drop of the sample was examined under light microscope and images acquired with Nikon Eclipse Ti (Nikon Instruments). Purified cells were stored at -80 °C until required.
The paired two-tailed Student's t test was used for statistical analysis and a p value of 0.05 was considered significant. Error bars represent standard deviations.
human immunodeficiency virus
murine leukemia viruses
murine acquired immunodeficiency syndrome.
This research was supported by University of Iowa Startup funds to CMO. PHJ was supported by Immunology T32 training grant to the University of Iowa. The following reagent was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: SC-1/MLV LP-BM5 from Dr. Herbert Morse and Dr. Janet Hartley. Radiation experiments were made possible by the Radiation and Free Radical Research Core Facility of the University of Iowa and Holden Comprehensive Cancer Center Support Grant P30 CA086862. We would like to thank Bryson Okeoma for his analytical critique of this manuscript.
- Cameron DW, Simonsen JN, D'Costa LJ, Ronald AR, Maitha GM, Gakinya MN, Cheang M, Ndinya-Achola JO, Piot P, Brunham RC, et al: Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet. 1989, 2: 403-407.View ArticlePubMedGoogle Scholar
- Clumeck N, Taelman H, Hermans P, Piot P, Schoumacher M, De Wit S: A cluster of HIV infection among heterosexual people without apparent risk factors. N Engl J Med. 1989, 321: 1460-1462. 10.1056/NEJM198911233212107.View ArticlePubMedGoogle Scholar
- Royce RA, Sena A, Cates W, Cohen MS: Sexual transmission of HIV. N Engl J Med. 1997, 336: 1072-1078. 10.1056/NEJM199704103361507.View ArticlePubMedGoogle Scholar
- Vernazza PL, Eron JJ, Fiscus SA, Cohen MS: Sexual transmission of HIV: infectiousness and prevention. AIDS. 1999, 13: 155-166. 10.1097/00002030-199902040-00003.View ArticlePubMedGoogle Scholar
- Byrn RA, Zhang D, Eyre R, McGowan K, Kiessling AA: HIV-1 in semen: an isolated virus reservoir. Lancet. 1997, 350: 1141-10.1016/S0140-6736(97)24042-0.View ArticlePubMedGoogle Scholar
- Delwart EL, Mullins JI, Gupta P, Learn GH, Holodniy M, Katzenstein D, Walker BD, Singh MK: Human immunodeficiency virus type 1 populations in blood and semen. J Virol. 1998, 72: 617-623.PubMed CentralPubMedGoogle Scholar
- Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC: Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J Infect Dis. 1994, 170: 1292-1295. 10.1093/infdis/170.5.1292.View ArticlePubMedGoogle Scholar
- Taylor S, Boffito M, Vernazza PL: Antiretroviral therapy to reduce the sexual transmission of HIV. J HIV Ther. 2003, 8: 55-66.PubMedGoogle Scholar
- Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M: HIV-1 drug resistance in newly infected individuals. JAMA. 1999, 282: 1135-1141. 10.1001/jama.282.12.1135.View ArticlePubMedGoogle Scholar
- Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS, Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD, Richman DD: Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999, 282: 1142-1149. 10.1001/jama.282.12.1142.View ArticlePubMedGoogle Scholar
- Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, Kahn JO: Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998, 339: 307-311. 10.1056/NEJM199807303390504.View ArticlePubMedGoogle Scholar
- Cu-Uvin S, DeLong AK, Venkatesh KK, Hogan JW, Ingersoll J, Kurpewski J, De Pasquale MP, D'Aquila R, Caliendo AM: Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS. 2010, 24: 2489-2497. 10.1097/QAD.0b013e32833e5043.View ArticlePubMedGoogle Scholar
- Cu-Uvin S, Caliendo AM: Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS. 2011, 25: 880-881. 10.1097/QAD.0b013e328344ccf8.View ArticlePubMedGoogle Scholar
- Mosier DE: Animal models for retrovirus-induced immunodeficiency disease. Immunol Invest. 1986, 15: 233-261. 10.3109/08820138609026687.View ArticlePubMedGoogle Scholar
- Chattopadhyay SK, Morse HC, Makino M, Ruscetti SK, Hartley JW: Defective virus is associated with induction of murine retrovirus-induced immunodeficiency syndrome. Proc Natl Acad Sci U S A. 1989, 86: 3862-3866. 10.1073/pnas.86.10.3862.PubMed CentralView ArticlePubMedGoogle Scholar
- Chattopadhyay SK, Sengupta DN, Fredrickson TN, Morse HC, Hartley JW: Characteristics and contributions of defective, ecotropic, and mink cell focus-inducing viruses involved in a retrovirus-induced immunodeficiency syndrome of mice. J Virol. 1991, 65: 4232-4241.PubMed CentralPubMedGoogle Scholar
- Jolicoeur P: Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. FASEB J. 1991, 5: 2398-2405.PubMedGoogle Scholar
- Morse HC, Yetter RA, Via CS, Hardy RR, Cerny A, Hayakawa K, Hugin AW, Miller MW, Holmes KL, Shearer GM: Functional and phenotypic alterations in T cell subsets during the course of MAIDS, a murine retrovirus-induced immunodeficiency syndrome. J Immunol. 1989, 143: 844-850.PubMedGoogle Scholar
- Morse HC, Chattopadhyay SK, Makino M, Fredrickson TN, Hugin AW, Hartley JW: Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS. 1992, 6: 607-621.View ArticlePubMedGoogle Scholar
- Yetter RA, Buller RM, Lee JS, Elkins KL, Mosier DE, Fredrickson TN, Morse HC: CD4+ T cells are required for development of a murine retrovirus-induced immunodeficiency syndrome (MAIDS). J Exp Med. 1988, 168: 623-635. 10.1084/jem.168.2.623.View ArticlePubMedGoogle Scholar
- Cerny A, Hugin AW, Hardy RR, Hayakawa K, Zinkernagel RM, Makino M, Morse HC: B cells are required for induction of T cell abnormalities in a murine retrovirus-induced immunodeficiency syndrome. J Exp Med. 1990, 171: 315-320. 10.1084/jem.171.1.315.View ArticlePubMedGoogle Scholar
- Cerny A, Hugin AW, Holmes KL, Morse HC: CD4+ T cells in murine acquired immunodeficiency syndrome: evidence for an intrinsic defect in the proliferative response to soluble antigen. Eur J Immunol. 1990, 20: 1577-1581. 10.1002/eji.1830200725.View ArticlePubMedGoogle Scholar
- Hartley JW, Fredrickson TN, Yetter RA, Makino M, Morse HC: Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differing susceptibility of inbred mouse strains. J Virol. 1989, 63: 1223-1231.PubMed CentralPubMedGoogle Scholar
- Pozsgay JM, Beilharz MW, Wines BD, Hess AD, Pitha PM: The MA (p15) and p12 regions of the gag gene are sufficient for the pathogenicity of the murine AIDS virus. J Virol. 1993, 67: 5989-5999.PubMed CentralPubMedGoogle Scholar
- Fraternale A, Casabianca A, Tonelli A, Vallanti G, Chiarantini L, Brandi G, Celeste AG, Magnani M: Inhibition of murine AIDS by alternate administration of azidothymidine and fludarabine monophosphate. J Acquir Immune Defic Syndr. 2000, 23: 209-220.View ArticlePubMedGoogle Scholar
- Fraternale A, Tonelli A, Casabianca A, Chiarantini L, Schiavano GF, Celeste AG, Magnani M: New treatment protocol including lympholytic and antiretroviral drugs to inhibit murine AIDS. J Acquir Immune Defic Syndr. 2000, 23: 107-113.View ArticlePubMedGoogle Scholar
- Mayhew CN, Sumpter R, Inayat M, Cibull M, Phillips JD, Elford HL, Gallicchio VS: Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease. Antiviral Res. 2005, 65: 13-22. 10.1016/j.antiviral.2004.09.003.View ArticlePubMedGoogle Scholar
- Beilharz MW, Sammels LM, Paun A, Shaw K, van Eeden P, Watson MW, Ashdown ML: Timed ablation of regulatory CD4+ T cells can prevent murine AIDS progression. J Immunol. 2004, 172: 4917-4925.View ArticlePubMedGoogle Scholar
- Dias AS, Bester MJ, Britz RF, Apostolides Z: Animal models used for the evaluation of antiretroviral therapies. Curr HIV Res. 2006, 4: 431-446. 10.2174/157016206778560045.View ArticlePubMedGoogle Scholar
- Patterson BK, Landay A, Siegel JN, Flener Z, Pessis D, Chaviano A, Bailey RC: Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol. 2002, 161: 867-873. 10.1016/S0002-9440(10)64247-2.PubMed CentralView ArticlePubMedGoogle Scholar
- Johansson EL, Rudin A, Wassen L, Holmgren J: Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology. 1999, 96: 272-277. 10.1046/j.1365-2567.1999.00675.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Olaitan A, Johnson MA, MacLean A, Poulter LW: The distribution of immunocompetent cells in the genital tract of HIV-positive women. AIDS. 1996, 10: 759-764.View ArticlePubMedGoogle Scholar
- Edwards JN, Morris HB: Langerhans' cells and lymphocyte subsets in the female genital tract. Br J Obstet Gynaecol. 1985, 92: 974-982. 10.1111/j.1471-0528.1985.tb03080.x.View ArticlePubMedGoogle Scholar
- Hladik F, Lentz G, Delpit E, McElroy A, McElrath MJ: Coexpression of CCR5 and IL-2 in human genital but not blood T cells: implications for the ontogeny of the CCR5+ Th1 phenotype. J Immunol. 1999, 163: 2306-2313.PubMedGoogle Scholar
- Zhang L, He T, Talal A, Wang G, Frankel SS, Ho DD: In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol. 1998, 72: 5035-5045.PubMed CentralPubMedGoogle Scholar
- Prakash M, Kapembwa MS, Gotch F, Patterson S: Higher levels of activation markers and chemokine receptors on T lymphocytes in the cervix than peripheral blood of normal healthy women. J Reprod Immunol. 2001, 52: 101-111. 10.1016/S0165-0378(01)00114-0.View ArticlePubMedGoogle Scholar
- Pichlmair A, Reis E, Sousa C: Innate recognition of viruses. Immunity. 2007, 27: 370-383. 10.1016/j.immuni.2007.08.012.View ArticlePubMedGoogle Scholar
- Chiu YH, Macmillan JB, Chen ZJ: RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell. 2009, 138: 576-591. 10.1016/j.cell.2009.06.015.PubMed CentralView ArticlePubMedGoogle Scholar
- Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V: RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol. 2009, 10: 1065-1072. 10.1038/ni.1779.View ArticlePubMedGoogle Scholar
- Martinon F, Mayor A, Tschopp J: The inflammasomes: guardians of the body. Annu Rev Immunol. 2009, 27: 229-265. 10.1146/annurev.immunol.021908.132715.View ArticlePubMedGoogle Scholar
- Bhattacharya C, Aggarwal S, Kumar M, Ali A, Matin A: Mouse apolipoprotein B editing complex 3 (APOBEC3) is expressed in germ cells and interacts with dead-end (DND1). PLoS One. 2008, 3: e2315-10.1371/journal.pone.0002315.PubMed CentralView ArticlePubMedGoogle Scholar
- Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH: Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol. 2009, 83: 9474-9485. 10.1128/JVI.01089-09.PubMed CentralView ArticlePubMedGoogle Scholar
- LaRue RS, Jonsson SR, Silverstein KA, Lajoie M, Bertrand D, El-Mabrouk N, Hotzel I, Andresdottir V, Smith TP, Harris RS: The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol. 2008, 9: 104-10.1186/1471-2199-9-104.PubMed CentralView ArticlePubMedGoogle Scholar
- Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB: A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A. 2004, 101: 6062-6067. 10.1073/pnas.0400782101.PubMed CentralView ArticlePubMedGoogle Scholar
- Okeoma CM, Lovsin N, Peterlin BM, Ross SR: APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature. 2007, 445: 927-930. 10.1038/nature05540.View ArticlePubMedGoogle Scholar
- Okeoma CM, Low A, Bailis W, Fan HY, Peterlin BM, Ross SR: Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection. J Virol. 2009, 83: 3486-3495. 10.1128/JVI.02347-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Okeoma CM, Huegel AL, Lingappa J, Feldman MD, Ross SR: APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe. 2010, 8: 534-543. 10.1016/j.chom.2010.11.003.PubMed CentralView ArticlePubMedGoogle Scholar
- Cullen BR: HIV-1 Vif: counteracting innate antiretroviral defenses. Mol Ther. 2003, 8: 525-527. 10.1016/j.ymthe.2003.08.010.View ArticlePubMedGoogle Scholar
- Chiu YL, Greene WC: Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol. 2006, 27: 291-297. 10.1016/j.it.2006.04.003.View ArticlePubMedGoogle Scholar
- Malim MH: APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci. 2009, 364: 675-687. 10.1098/rstb.2008.0185.PubMed CentralView ArticlePubMedGoogle Scholar
- Okeoma CM, Petersen J, Ross SR: Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J Virol. 2009, 83: 3029-3038. 10.1128/JVI.02536-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Low A, Okeoma CM, Lovsin N, De Las Heras M, Taylor TH, Peterlin BM, Ross SR, Fan H: Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology. 2009, 385: 455-463. 10.1016/j.virol.2008.11.051.PubMed CentralView ArticlePubMedGoogle Scholar
- Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH: Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol. 2004, 14: 1392-1396. 10.1016/j.cub.2004.06.057.View ArticlePubMedGoogle Scholar
- Bishop KN, Holmes RK, Sheehy AM, Malim MH: APOBEC-mediated editing of viral RNA. Science. 2004, 305: 645-10.1126/science.1100658.View ArticlePubMedGoogle Scholar
- Holmes RK, Koning FA, Bishop KN, Malim MH: APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem. 2007, 282: 2587-2595.View ArticlePubMedGoogle Scholar
- Aguiar RS, Lovsin N, Tanuri A, Peterlin BM: Vpr.A3A chimera inhibits HIV replication. J Biol Chem. 2008, 283: 2518-2525.View ArticlePubMedGoogle Scholar
- Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002, 418: 646-650. 10.1038/nature00939.View ArticlePubMedGoogle Scholar
- Conticello SG, Harris RS, Neuberger MS: The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol. 2003, 13: 2009-2013. 10.1016/j.cub.2003.10.034.View ArticlePubMedGoogle Scholar
- Marin M, Rose KM, Kozak SL, Kabat D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med. 2003, 9: 1398-1403. 10.1038/nm946.View ArticlePubMedGoogle Scholar
- Takeda E, Tsuji-Kawahara S, Sakamoto M, Langlois MA, Neuberger MS, Rada C, Miyazawa M: Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol. 2008, 82: 10998-11008. 10.1128/JVI.01311-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Langlois MA, Neuberger MS: Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J Virol. 2008, 82: 4660-4664. 10.1128/JVI.02469-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Huang M, Simard C, Jolicoeur P: Immunodeficiency and clonal growth of target cells induced by helper-free defective retrovirus. Science. 1989, 246: 1614-1617. 10.1126/science.2480643.View ArticlePubMedGoogle Scholar
- Simard C, Huang M, Jolicoeur P: Murine AIDS is initiated in the lymph nodes draining the site of inoculation, and the infected B cells influence T cells located at distance, in noninfected organs. J Virol. 1994, 68: 1903-1912.PubMed CentralPubMedGoogle Scholar
- Huang M, Jolicoeur P: Myristylation of Pr60gag of the murine AIDS-defective virus is required to induce disease and notably for the expansion of its target cells. J Virol. 1994, 68: 5648-5655.PubMed CentralPubMedGoogle Scholar
- Huang M, Simard C, Kay DG, Jolicoeur P: The majority of cells infected with the defective murine AIDS virus belong to the B-cell lineage. J Virol. 1991, 65: 6562-6571.PubMed CentralPubMedGoogle Scholar
- Iwashiro M, Messer RJ, Peterson KE, Stromnes IM, Sugie T, Hasenkrug KJ: Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection. Proc Natl Acad Sci U S A. 2001, 98: 9226-9230. 10.1073/pnas.151174198.PubMed CentralView ArticlePubMedGoogle Scholar
- Okeoma CM, Shen M, Ross SR: A novel block to mouse mammary tumor virus infection of lymphocytes in B10.BR mice. J Virol. 2008, 82: 1314-1322. 10.1128/JVI.01848-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Pilcher CD, Shugars DC, Fiscus SA, Miller WC, Menezes P, Giner J, Dean B, Robertson K, Hart CE, Lennox JL, Eron JJ, Hicks CB: HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS. 2001, 15: 837-845. 10.1097/00002030-200105040-00004.View ArticlePubMedGoogle Scholar
- Pilcher CD, Eron JJ, Vemazza PL, Battegay M, Harr T, Yerly S, Vom S, Perrin L: Sexual transmission during the incubation period of primary HIV infection. JAMA. 2001, 286: 1713-1714. 10.1001/jama.286.14.1713.View ArticlePubMedGoogle Scholar
- Whitney JB, Luedemann C, Hraber P, Rao SS, Mascola JR, Nabel GJ, Letvin NL: T-cell vaccination reduces simian immunodeficiency virus levels in semen. J Virol. 2009, 83: 10840-10843. 10.1128/JVI.01202-09.PubMed CentralView ArticlePubMedGoogle Scholar
- Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000, 342: 921-929. 10.1056/NEJM200003303421303.View ArticlePubMedGoogle Scholar
- Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, vanCott T, Quinn TC: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001, 357: 1149-1153. 10.1016/S0140-6736(00)04331-2.View ArticlePubMedGoogle Scholar
- Okada Y, Abe E, Komuro K, Mizuochi T: Heterosexual transmission of a murine AIDS virus. J Virol. 1998, 72: 2541-2543.PubMed CentralPubMedGoogle Scholar
- Roan NR, Muller JA, Liu H, Chu S, Arnold F, Sturzel CM, Walther P, Dong M, Witkowska HE, Kirchhoff F, Munch J, Greene WC: Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe. 2011, 10: 541-550. 10.1016/j.chom.2011.10.010.PubMed CentralView ArticlePubMedGoogle Scholar
- van Leeuwen E, de Vries JW, Jurriaans S, Verhoeve HR, Prins JM, Repping S, van der Veen F: Intra uterine insemination with processed sperm for HIV serodiscordant couples in whom the man is HIV positive. Ned Tijdschr Geneeskd. 2005, 149: 423-424.PubMedGoogle Scholar
- Mermin JH, Holodniy M, Katzenstein DA, Merigan TC: Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis. 1991, 164: 769-772. 10.1093/infdis/164.4.769.View ArticlePubMedGoogle Scholar
- Nuovo GJ, Becker J, Simsir A, Margiotta M, Khalife G, Shevchuk M: HIV-1 nucleic acids localize to the spermatogonia and their progeny. A study by polymerase chain reaction in situ hybridization. Am J Pathol. 1994, 144: 1142-1148.PubMed CentralPubMedGoogle Scholar
- Bagasra O, Farzadegan H, Seshamma T, Oakes JW, Saah A, Pomerantz RJ: Detection of HIV-1 proviral DNA in sperm from HIV-1-infected men. AIDS. 1994, 8: 1669-1674. 10.1097/00002030-199412000-00005.View ArticlePubMedGoogle Scholar
- Bagasra O, Freund M, Weidmann J, Harley G: Interaction of human immunodeficiency virus with human sperm in vitro. J Acquir Immune Defic Syndr. 1988, 1: 431-435.PubMedGoogle Scholar
- Bagasra O, Patel D, Bobroski L, Abbasi JA, Bagasra AU, Baidouri H, Harris T, El-Roeiy A, Lengvarszky Z, Farzadegan H, Wood C: Localization of human herpesvirus type 8 in human sperms by in situ PCR. J Mol Histol. 2005, 36: 401-412.View ArticlePubMedGoogle Scholar
- Doehle BP, Schafer A, Wiegand HL, Bogerd HP, Cullen BR: Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J Virol. 2005, 79: 8201-8207. 10.1128/JVI.79.13.8201-8207.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Abudu A, Takaori-Kondo A, Izumi T, Shirakawa K, Kobayashi M, Sasada A, Fukunaga K, Uchiyama T: Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms. Curr Biol. 2006, 16: 1565-1570. 10.1016/j.cub.2006.06.055.View ArticlePubMedGoogle Scholar
- Dey A, Mantri CK, Pandhare-Dash J, Liu B, Pratap S, Dash C: Downregulation of APOBEC3G by xenotropic murine leukemia-virus related virus (XMRV) in prostate cancer cells. Virol J. 2011, 8: 531-10.1186/1743-422X-8-531.PubMed CentralView ArticlePubMedGoogle Scholar
- Mosier DE, Yetter RA, Morse HC: Functional T lymphocytes are required for a murine retrovirus-induced immunodeficiency disease (MAIDS). J Exp Med. 1987, 165: 1737-1742. 10.1084/jem.165.6.1737.View ArticlePubMedGoogle Scholar
- Cook WJ, Green KA, Obar JJ, Green WR: Quantitative analysis of LP-BM5 murine leukemia retrovirus RNA using real-time RT-PCR. J Virol Methods. 2003, 108: 49-58. 10.1016/S0166-0934(02)00256-2.View ArticlePubMedGoogle Scholar
- Jones PH, Mehta HV, Maric M, Roller RJ, Okeoma CM: Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo. Retrovirology. 2012, 9: 10-10.1186/1742-4690-9-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Giese NA, Giese T, Morse HC: Murine AIDS is an antigen-driven disease: requirements for major histocompatibility complex class II expression and CD4+ T cells. J Virol. 1994, 68: 5819-5824.PubMed CentralPubMedGoogle Scholar
- Lasheeb AS, King J, Ball JK, Curran R, Barratt CL, Afnan M, Pillay D: Semen characteristics in HIV-1 positive men and the effect of semen washing. Genitourin Med. 1997, 73: 303-305.PubMed CentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.